Overview
Corporate Profile
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with cancer and other serious diseases. We harness our NAM-enabled technology platform to create therapies with the potential to improve the course of cancer care.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest News
View All
Sep 28, 2021
Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline
Read More
Sep 02, 2021
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September
Read More
Aug 11, 2021
Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update
Read More
Aug 04, 2021
Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast
Read More
Jun 23, 2021
Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant
Read More
Jun 09, 2021
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June
Read More
Jun 07, 2021
Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update
Read More
May 12, 2021
Gamida Cell to Present at the RBC Capital Markets Global Healthcare Conference
Read More
May 11, 2021
Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update
Read More
May 04, 2021
Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and Webcast
Read More
Apr 07, 2021
Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference
Read More
Mar 15, 2021
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Read More
Mar 09, 2021
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update
Read More
Mar 02, 2021
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast
Read More
Mar 01, 2021
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Read More
Feb 16, 2021
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management
Read More
Feb 09, 2021
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR
Read More
Jan 11, 2021
Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
Read More
Upcoming Events
Oct 26, 2021 at 8:00 AM EDT
Recent Events
Corporate Fact Sheet
Corporate Presentation
In the News
July 20, 2021
Source
ASH Clinical News
July 16, 2021
Source
GeneTherapyLive
June 23, 2021
Source
Cell & Gene
June 22, 2021
Source
GeneTherapyLive
March 26, 2021
Source
Pharmacy Times
Investor & Media Contact
Josh Hamermesh
Chief Business Officer
Gamida Cell Ltd.
IRPR@gamida-cell.com